Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.

April 10, 2026

Vol.52 No.14

By Claire Marie Porter and Paul Goldberg

Cancer Policy

President’s budget request would cap indirect costs and fully fund all NIH research projects upfront

NCI has emerged relatively unscathed in the president’s FY 2027 budget request that would slash $15.8 billion from HHS funding, cut NIH overall by about 10%, eliminate three NIH institutes and centers, and move the Institute for Environmental Health Sciences and its circa $1 billion budget out of NIH.

April 10, 2026

Vol.52 No.14

By Claire Marie Porter and Jacquelyn Cobb

Drugs & Targets

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Vol.52 No.13

Podcast The Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).

March 27, 2026

Vol.52 No.12

By Sara Willa Ernst and Paul Goldberg

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

YOU MAY BE INTERESTED IN

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

President’s budget request would cap indirect costs and fully fund all NIH research projects upfront

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Renew today!

Subscriber content

Never miss an issue!

Login

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

YOU MAY BE INTERESTED IN

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdyNCI expects record-breaking spending on extramural research

President’s budget request would cap indirect costs and fully fund all NIH research projects upfront

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Never miss an issue!

Login

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research